Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 6Dermatologic 5Breast 2Thoracic 1Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × tanespimycin × Breast × Clear all
NCT00096109 2017-01-16

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
11 enrolled 6 charts
Breast

Breast Neoplasms

NCT00817362 2012-12-11

Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer

Infinity Pharmaceuticals, Inc.

Phase 2 Terminated
29 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡